Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ashley Newcombe"'
Autor:
Anne-Louise Latif, Ashley Newcombe, Sha Li, Kathryn Gilroy, Neil A. Robertson, Xue Lei, Helen J. S. Stewart, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Andrew Davis, Jonathan Lopez, Jun-ichi Sakamaki, Jennifer P. Morton, Kevin M. Ryan, Stephen W. G. Tait, Sheela A. Abraham, Tessa Holyoake, Brian Higgins, Xu Huang, Karen Blyth, Mhairi Copland, Timothy J. T. Chevassut, Karen Keeshan, Peter D. Adams
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
MDM2 and BET inhibitors have shown efficacy in AML treatment. Here, the authors show that the two compounds can synergize through both p53 protein stabilization and inhibition of BRD4-mediated repression of p53 target genes.
Externí odkaz:
https://doaj.org/article/4058dbf2924543a399c2f17c8fd2a6ad
Autor:
Andrew Davis, Helen Stewart, Kristina Kirschner, Tessa L. Holyoake, William C. Clark, Ashley Newcombe, Xu Huang, John J. Cole, Anne-Louise Latif, Joana Campos, Stephen W.G. Tait, Kevin M. Ryan, Lynn McGarry, Loveena Rishi, Claire Reid, Jun-ichi Sakamaki, Sheela A. Abraham, Brian Higgins, Claire McKeeve, Xue Lei, Neil Robertson, Karen Blyth, Jennifer P. Morton, Timothy Chevassut, Mhairi Copland, Jonathan Lopez, Kathryn Gilroy, Karen Keeshan, Peter D. Adams, Sha Li, Maria Terradas Terradas
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Acute myeloid leukemia (AML) is a typically lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, most AML retain wild-type TP53, encoding the pro-apoptotic tumor suppressor p53. MDM2 inhibitors (MDM2i), wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::813a0a41aaea00f9398f4b139324ead4
https://doi.org/10.1101/2020.09.16.291930
https://doi.org/10.1101/2020.09.16.291930
Autor:
John J. Cole, Neil Robertson, Anne-Louise Latif, Andrew Davis, Jonathan Lopez, Lynn McGarry, Tessa L. Holyoake, Karen Keeshan, Claire Reid, Aniruddha J. Deshpande, Peter D. Adams, Kathryn Gilrory, Kristina Kirschner, Karen Blyth, Ashley Newcombe, Karina Barbosa, Loveena Rishi Delori, Mhairi Copland, Timothy Chevassut, Sheela A. Abraham, Xu Huang, Helen Stewart, William C. Clark, Stephen W.G. Tait, Xue Lei, Darren Finlay, Kevin M. Ryan, Jennifer P. Morton, Sha Li, Joana Campos, Maria Terradas Terradas, Claire McKeeve, Jun-ichi Sakamaki, Brian Higgins
Publikováno v:
Blood. 136:14-14
Acute Myeloid Leukemia (AML) is a typically-lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually compared to many other cancers, over 90% of AML patients retain wild type TP53, encoding pro-apoptotic tumor
Autor:
Peter D. Adams, Darren Finlay, Anne Louise Latif, Mhairi Copland, Helen Stewart, Ashley Newcombe, Neil Robertson, Brian Higgins, Sha Li, Kathryn Gilroy, Ani Deshpande, Karina Barbosa, Timothy Chevassut, Xu Huang, Karen Keeshan, Xue Lei
Publikováno v:
Cancer Research. 80:3426-3426
Acute Myeloid Leukemia (AML) is a typically-lethal molecularly heterogeneous disease, with few broad-spectrum therapeutic targets. Unusually, over 90% of AML patients retain wild type TP53, encoding pro-apoptotic tumor suppressor p53. However, wild-t
Autor:
Sha Li, Anne-Louise Latif, Ashley Newcombe, Kathryn Gilrory, Neil Robertson, Darren Finlay, Xue Lei, Helen Stewart, Karina Barbosa, John Cole, Maria Terradas Terradas, Loveena Rishi, Lynn McGarry, Claire McKeeve, Claire Reid, William Clark, Joana Campos, Kristina Kirschner, Jonathan Lopez, Jun-Ichi Sakamaki, Jennifer Morton, Kevin Ryan, Stephen Tait, Sheela Abraham, Tessa Holyoake, Brian Higgins, Xu Huang, Mhairi Copland, Tim Chevassut, Ani Deshpande, Karen Keeshan, Peter Adams
Publikováno v:
Experimental Hematology. 88:S70
Publikováno v:
Experimental hematology. 63
There is a desperate need for new and effective therapeutic approaches to acute myeloid leukemia (AML) in both children and adults. Epigenetic aberrations are common in adult AML, and many novel epigenetic compounds that may improve patient outcomes
Autor:
Neil Robertson, Anne Louise Latif, Ashley Newcombe, Peter D. Adams, Helen Stewart, Karen Blyth, Maria Terradas Terradas, Loveena Rishi Delori, Xu Huang, Claire Reid, Karen Keeshan, Timothy Chevassut, Mhairi Copland
Publikováno v:
Blood. 132:3912-3912
In 2016, there will be approximately 19,950 new cases of Acute Myeloid Leukaemia (AML) in the United States. After diagnosis, five-year survival is currently ~26%, with available therapeutic approaches. Therefore, there remains a critical requirement
Publikováno v:
Endocrine Abstracts.
Autor:
Anne-Louise Latif, Peter D. Adams, Claire Brock, Mhairi Copland, Joana Campos, Willliam Clark, Lynn McGarry, John J. Cole, Karen Keeshan, Ashley Newcombe
Publikováno v:
Blood. 126:674-674
Background: There remains a critical requirement for novel therapies for Acute Myeloid Leukemia (AML). Bromodomain and extra-terminal domain (BET) inhibitors are emerging as exciting therapeutic agents for hematopoietic malignancies. Pharmacological